Clinical Trial

Study of Stapokibart Injection in Patients With Allergic Rhinitis

Study acronym: MIZAR
Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated November 8, 2024 (before its estimated October 30, 2025 completion). Its status may not reflect the trial's current state.
Summary
This study is a Randomized, Double-blind, Placebo-controlled phase II clinical study evaluating the efficacy and safety of Stapokibart injection in patients with allergic rhinitis.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2024-07-24; most recent amendment 2024-11-07.
Status change: Not Yet Recruiting → Recruiting 2024-11-07
Trial Details
NCT Number NCT06525597
Lead Sponsor Keymed Biosciences Co.Ltd
Conditions Allergic Rhinitis
Enrollment 120 participants
Start Date 2024-09-30
Primary Completion 2025-10-30 (estimated)
Study Completion 2025-10-30 (estimated)
Updated on ClinicalTrials.gov 2024-11-08